Breast Cancer Research and Treatment最新文献

{"title":"Omission of multimodal therapy in older adults with high-risk breast cancer.","authors":"Eliza H Lorentzen, Yu-Jen Chen, Annabelle L Jones, Olga Kantor, Tari A King, Elizabeth A Mittendorf, Christina A Minami","doi":"10.1007/s10549-025-07728-0","DOIUrl":"10.1007/s10549-025-07728-0","url":null,"abstract":"<p><strong>Purpose: </strong>Treatment guidelines recommend multimodal therapy for non-metastatic high-risk breast cancer in older adults. However, older patients may be less likely to receive this due to varying abilities to withstand intensive therapy. We aimed to quantify the incidence of, factors associated with, and reasons behind omission of multimodal therapy in older high-risk breast cancer patients.</p><p><strong>Methods: </strong>Women ≥ 70 years diagnosed with stage 2-3 HR-/HER2+ or triple-negative breast cancer were identified in the National Cancer Database, 2010-2020. Multimodal therapy was defined as surgery and systemic therapy; omission of multimodal therapy was defined as patients who did not receive one or both therapies. Chi-square tests were used to assess differences by therapy intensity. Multivariable logistic regression models adjusting for patient and disease-level characteristics were performed to determine the factors associated with therapy omission.</p><p><strong>Results: </strong>Of 22,644 patients, 63.4% were ≤ 80 years old. Overall, 59.7% received multimodal therapy, 35.3% received either surgery or systemic therapy, and 5.0% received no therapy. Factors significantly associated with increased likelihood of multimodal therapy omission included increased age, Black race, Medicaid or uninsured status, and higher Charlson Comorbidity Index scores. The most common reason for omission was that it was \"not part of planned treatment,\" (59.2% for omission of surgery, 52.4% for omission of systemic therapy), with patient refusal (17.4% for omission of surgery, 28.3% for omission of systemic therapy) being second most common.</p><p><strong>Conclusions: </strong>While most older patients received multimodal therapy, demographic and socioeconomic factors associated with treatment omission suggest that some vulnerable women with high-risk disease may be undertreated.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"337-346"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study.","authors":"Tori C Nierenberg, Samantha M Thomas, Ian Halliday, Astrid Botty van den Bruele, Akiko Chiba, Kendra J Modell Parrish, Hannah E Woriax, Maggie L DiNome, Kelly E Westbrook, Jennifer K Plichta","doi":"10.1007/s10549-025-07717-3","DOIUrl":"10.1007/s10549-025-07717-3","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant therapies can result in pathologic complete response (pCR) in patients with breast cancer, which can be predictive of long-term outcomes. Patients with estrogen receptor positive (ER +) tumors may receive either neoadjuvant chemotherapy (NAC) or neoadjuvant endocrine therapy (NET). We sought to compare survival outcomes in those with non-metastatic ER + breast cancer who received NET or NAC and achieved pCR.</p><p><strong>Methods: </strong>All patients diagnosed with ER + /HER2- stage I-III breast cancer, who received neoadjuvant systemic therapy followed by surgery, and achieved pCR, were selected from the National Cancer Database (NCDB, 2010-2021). The Kaplan-Meier method was used to estimate overall survival (OS), and log-rank tests were used to test for differences in OS. Cox Proportional Hazards models were used to estimate the association of NAC vs NET with OS, after adjustment for covariates.</p><p><strong>Results: </strong>3313 patients met eligibility criteria: 3148 received NAC and 165 NET. The median follow-up for the entire cohort was 82 months (95% CI 80.4-83.1). Patients who received NAC were significantly younger (median age: NAC 49y vs NET 64y; p < 0.001), more likely to have a comorbidity score of 0 (NAC 89.3% vs NET 81.2%, p = 0.004), and more likely to have private insurance (NAC 68.9% vs NET 44.2%, p < 0.001). There were no significant differences between the NAC and NET patients based on race and ethnicity, income, education, or community type (all p > 0.05). The NAC treated patients were more likely to have larger tumors [median tumor size (IQR): NAC 3 cm (2.0-4.3) vs NET 1.3 cm (0.7-2.8); p < 0.001)], ductal histology (NAC 92.6% vs 81.2%, p < 0.001), and grade 3 tumors (NAC 70.2% vs 10.3%, p < 0.001). In the unadjusted Kaplan-Meier analysis, there was no significant difference in OS between NAC vs NET [5-year OS: NAC 0.935 vs NET 0.916; p = 0.08]. After adjustment for demographics, disease characteristics, and treatments, there remained no association between OS and study group (NAC vs NET; p = 0.63).</p><p><strong>Conclusions: </strong>Patients with ER + /HER2- early-stage breast cancer who achieved pCR had similar OS, regardless of whether they received NAC or NET. As such, pCR appears to have similar prognostic value irrespective of the type of systemic therapy used to obtain this favorable outcome.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"161-172"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer.","authors":"Connie Lau, Krista LaBorde, Bilqees Fatima, Shahad S Alfartosy, Susan Abughosh, Rodrigo De La Torre, Erika N Brown, Meghana V Trivedi","doi":"10.1007/s10549-025-07701-x","DOIUrl":"10.1007/s10549-025-07701-x","url":null,"abstract":"<p><strong>Purpose: </strong>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy improve survival in patients with hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer (BC). This retrospective study aimed to evaluate CDK4/6i adherence, factors associated with non-adherence, the impact of health-system specialty pharmacy on adherence, and effects of non-adherence on survival outcomes in HR + /HER2- BC patients.</p><p><strong>Methods: </strong>Data was collected from Houston Methodist Hospital System (HM) from HR + /HER2- BC patients with medication fill history utilizing electronic medical records. CDK4/6i adherence was calculated using the mean possession ratio ≥ 80%. Multivariable logistic regression model and Kaplan-Meier analysis were utilized to evaluate factors associated with non-adherence and its impact on survival, respectively.</p><p><strong>Results: </strong>A total of 121 patients were assessed and analyzed; 55% patients received abemaciclib, 40% were on palbociclib, and 4% were on ribociclib. More patients were on aromatase inhibitors and tamoxifen (79%) than fulvestrant (21%). Most of the patients were Caucasian (64%), non-Hispanic or Latino (84%), and postmenopausal (66%). Overall, 52 patients (43%) were non-adherent. Patients ≥ 65 years of age (OR: 0.304, [95% CI: 0.110-0.840], P-value: 0.022) and those of Hispanic or Latino ethnicity (OR: 0.291, [95% CI: 0.086-0.985], P-value: 0.047) were more likely to be non-adherent to CDK4/6i. Non-adherence to CDK4/6i was associated with worse overall survival and progression-free survival.</p><p><strong>Conclusion: </strong>43% patients were non-adherent to CDK4/6i. Older patients and those of Hispanic ethnicity were more likely to be non-adherent. Non-adherent patients had worse survival outcomes, highlighting the unmet need to implement interventions to improve CDK4/6i adherence in these patients.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"71-78"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population-based analysis of breast cancer incidence and mortality: overall and age-specific temporal trends over 40-year period in Girona, Spain.","authors":"Arantza Sanvisens, Anna Vidal-Vila, Montse Puigdemont, Gemma Viñas, Ariadna Roqué-Lloveras, Sonia Del Barco, Ferran Pérez-Bueno, Jan Trallero, Rafael Marcos-Gragera, Gemma Renart","doi":"10.1007/s10549-025-07704-8","DOIUrl":"10.1007/s10549-025-07704-8","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) incidence and mortality in women have changed over time. This study aims to analyze population-level incidence and mortality trends over 40 years of observation.</p><p><strong>Methods: </strong>Population-based study of BC conducted by Girona Cancer Registry covering the period 1980-2019. Age-standardized incidence and mortality rates were calculated. Poisson change-point regression models were used to analyze trends, calculating the annual percentage change (APC).</p><p><strong>Results: </strong>A total of 12,283 diagnoses of invasive BC between 1980 and 2019. The overall age-standardized incidence rate was 109.9 (95% confidence intervals (CI) 104.4; 115.4) cases per 100,000 women-years. Trend analyses showed a statistically significant incidence increase of 4.2% per year from 1980 to 1994 (95%CI 3.3; 5.1), and a stabilization between 1994 and 2019, with an APC of 0.28% (95%CI - 0.04; 0.56). These trends were similar for the age groups 0-49 years and 50-69 years. In women over 69 years of age, an increase in incidence of 4.4% (95%CI 2.8; 6.0) per year was observed between 1980 and 1995 followed by a non-statistically significant decrease of - 0.35% (95%CI - 0.86; 0.15) between 1995 and 2019. The overall age-standardized mortality rate was 30.3 (95%CI 29.3; 31.3) cases per 100,000 women-years. Mortality rate trends showed a statistically significant decrease of - 1.87% (95%CI - 2.38; - 1.37) per year since 1992.</p><p><strong>Conclusion: </strong>There has been a stabilization in the incidence of BC and a gradual decline in BC mortality in women. The introduction of mammography in the mid-1990s, alongside early detection and treatment due to screening programs may play a significant role in the reduction of BC burden in women of all ages.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"97-105"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes.","authors":"Ana Julia Aguiar de Freitas, Rhafaela Lima Causin, Stéphanie Calfa, Iara Viana Vidigal Santana, Mariana Balie, Welinton Hirai, Ana Carolina Laus, Hadson Silva Araujo, Cassio Murilo Hidalgo Filho, Fernanda de Oliveira Bombarda, Vinicius Duval da Silva, Adriane Feijó Evangelista, Cristiano de Pádua Souza, Rui Manuel Reis, Márcia Maria Chiquitelli Marques","doi":"10.1007/s10549-025-07718-2","DOIUrl":"10.1007/s10549-025-07718-2","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains a major global health concern due to its high incidence and mortality among women. Accurate prognostic stratification is essential for guiding treatment and improving outcomes. The Nottingham grading system evaluates tumor differentiation based on architectural features, nuclear atypia, and mitotic activity, serving as a key tool in assessing breast cancer prognosis.</p><p><strong>Objectives: </strong>To investigate gene expression patterns associated with histological grades and immunohistochemical subtypes of breast cancer, and to explore their relationship with clinical outcomes, including recurrence, overall survival (OS), and disease-free survival (DFS).</p><p><strong>Methods: </strong>In a cohort of 82 breast cancer patients, gene expression profiling was performed using the nCounter® Breast Cancer 360™ panel. Tumors were classified according to the Nottingham grading system. Differential gene expression analysis was conducted across histological grades and subtypes, with subsequent correlation to clinical outcomes.</p><p><strong>Results: </strong>Nearly half of the patients exhibited histological grade 3 tumors. Six genes-BIRC5, CDC6, FOXM1, TOP2A, MYBL2, and UBE2C-were significantly overexpressed in high-grade tumors. These genes are involved in key cell cycle regulatory pathways. Their overexpression was significantly associated with higher rates of disease recurrence and poorer OS and DFS, highlighting their prognostic value.</p><p><strong>Conclusions: </strong>This study reinforces the prognostic utility of histological grading and reveals a set of cell cycle-related genes whose overexpression is linked to adverse outcomes in breast cancer. These findings suggest potential biomarkers for risk stratification and therapeutic targeting, offering insights for personalized management of patients beyond traditional histological assessments.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"237-250"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the possibility of omitting axillary surgery in patients with clinical node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy.","authors":"Hideo Shigematsu, Momoko Takaya, Kanako Suzuki, Mutsumi Fujimoto, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Koji Arihiro, Morihito Okada","doi":"10.1007/s10549-025-07697-4","DOIUrl":"10.1007/s10549-025-07697-4","url":null,"abstract":"<p><strong>Purpose: </strong>Axillary staging is commonly performed in patients with clinically node-positive (cN+) breast cancer undergoing neoadjuvant chemotherapy (NACT), regardless of pathological complete response (pCR). Recent evidence has suggested that ypT0 correlates with ypN0 and favorable prognosis, potentially supporting the omission of axillary staging in such cases. This study aimed to evaluate ypT0 as a predictive factor for ypN status and its prognostic significance in cN+ breast cancer treated with NACT.</p><p><strong>Methods: </strong>This retrospective study included 302 patients with cN+ breast cancer treated with NACT at Hiroshima University Hospital between 2006 and 2022. Patients were categorized into non-pCR, ypTis, or ypT0 based on ypT status. Associations between breast pCR, ypN status, recurrence-free survival (RFS), and overall survival (OS) were analyzed.</p><p><strong>Results: </strong>Among 302 patients (non-pCR, 74.2%; ypTis, 8.9%; ypT0, 16.9%), the ypN+ rates were 63.3%, 15.2%, and 3.9%, respectively. Logistic regression revealed significant associations among ypT0, ypTis, and ypN0. The five-year RFS and OS rates were 78.6% and 85.2% (non-pCR), 83.8% and 95.5% (ypTis), and 98.0% and 100.0% (ypT0), respectively. Cox regression identified ypT0, but not ypTis, as a significant prognostic factor for both RFS and OS.</p><p><strong>Conclusion: </strong>ypT0 status was associated with a low risk of ypN+ and favorable clinical outcomes in cN+ breast cancer, suggesting the potential feasibility of omitting axillary surgery in select patients.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"47-56"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and performance of ultrafast sequences.","authors":"Justine Spriet, Aicha Ben Miled, Audrey Mailliez, Salomé Bonnier, Alexandra Forestier, Marie-Pierre Chauvet, Clémence Rozwag, Imen El Aoud, Luc Ceugnart","doi":"10.1007/s10549-025-07650-5","DOIUrl":"10.1007/s10549-025-07650-5","url":null,"abstract":"<p><strong>Background: </strong>Immunotherapy with pembrolizumab combined with neoadjuvant chemotherapy allows an improvement of pathological complete response rate in triple-negative breast cancer patients. The objective of the study is to evaluate the correlation between breast magnetic resonance imaging (MRI) findings and pathological response after NAC and immunotherapy. It also aims to compare the performances of an abbreviated protocol using ultrafast MRI (UF-MRI) sequences with that of full-protocol MRI (fpMRI).</p><p><strong>Methods: </strong>We conducted a single-center study including both retrospectively and prospectively triple-negative breast cancer patients, receiving neoadjuvant chemotherapy and pembrolizumab between May 2022 and June 2023. Breast MRI, including UF-MRI sequences, was performed to evaluate tumor response. These results were compared to those of postoperative pathological response.</p><p><strong>Results: </strong>Among the 36 patients included, 23 obtained pathological complete response. Herein, fpMRI protocol detected 18 complete tumor reduction, reflecting a sensitivity of 0.78 and a specificity of 0.69. The UF-MRI sequences alone showed 19 complete regressions of tumor with a sensitivity of 0.83 and with identical specificity. The agreement between the two MRI protocols was 0.96.</p><p><strong>Conclusion: </strong>The addition of immunotherapy to NAC does not prevent accurate MRI findings and tumor response prediction. Furthermore, the analysis of UF-MRI sequences as a stand-alone technique seems to be as efficient as the analysis of fpMRI, suggesting that abbreviated breast MRI could be incorporated into routine clinical practice.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"195-203"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.","authors":"Aleksandar M Kostov, Maj-Britt Jensen, Bent Ejlertsen, Mads Thomassen, Maria Rossing, Inge S Pedersen, Annabeth H Petersen, Lise Lotte Christensen, Karin A W Wadt, Luis C Berrocal-Almanza, Miguel Miranda, Anne-Vibeke Lænkholm","doi":"10.1007/s10549-025-07726-2","DOIUrl":"10.1007/s10549-025-07726-2","url":null,"abstract":"<p><strong>Purpose: </strong>To report the rates of risk-reducing surgery (RRS) following germline testing for BRCA1/2 (likely) pathogenic variants (BRCApv) and to assess the impact of RRS and BRCA status on survival after surgical treatment for unilateral breast cancer (BC).</p><p><strong>Methods: </strong>We identified 7145 women with BC (2000-2017), a BRCA test and median follow-up of 10.8 years from the Danish Breast Cancer Cooperative Group's clinical database. Distant recurrence-free (DRFS) and overall survival (OS) according to BRCA status were evaluated using the Kaplan-Meier method. Hazard ratios (HR) for BRCApv vs. BRCA wild-type, contralateral risk-reducing mastectomy (CRRM), and risk-reducing bilateral salpingo-oophorectomy (RRBSO), including interaction tests, were estimated using multivariable Cox models.</p><p><strong>Results: </strong>Among BRCA1pv carriers (n = 403), CRRM rates were higher than in BRCA2pv (n = 317) (66% vs. 52%, p < 0.001) and more likely to receive timely testing, i.e., within 6 months of BC diagnosis (75% vs. 52%, p = 0.004). Regarding RRBSO rates, no differences were observed. CRRM was associated with significantly improved DRFS (HR = 0.63, 95% CI 0.51-0.78) and OS (HR = 0.64, 95% CI 0.51-0.82), independently of BRCA status and age. RRBSO was associated with improved OS only in BRCApv carriers, specifically, those aged ≥ 50 years (HR = 0.44, 95% CI 0.26-0.75). BRCApv (irrespective of affected gene) was associated with worse DRFS (HR = 1.31, 95% CI 1.06-1.63); however, this was only evident after 2 years of follow-up (HR = 1.53, 95% CI 1.22-1.93). BRCApv was not significantly associated with worse OS (HR = 1.25, 95%CI 0.98-1.58).</p><p><strong>Conclusion: </strong>Timely germline testing at BC diagnosis might increase CRRM rates in BRCApv carriers, thereby improving survival.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"309-323"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limitations of locoregional and distant recurrence analysis after neoadjuvant chemotherapy.","authors":"Janhavi Venkataraman, Kefah Mokbel","doi":"10.1007/s10549-025-07680-z","DOIUrl":"10.1007/s10549-025-07680-z","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"183-184"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advantages of immediate implant-based breast reconstruction over delayed breast reconstruction in women treated with postmastectomy radiotherapy for breast cancer.","authors":"Merel M L Kooijman, J Joris Hage, Astrid N Scholten, Frederieke H van Duijnhoven, Corstiaan C Breugem, Leonie A E Woerdeman","doi":"10.1007/s10549-025-07690-x","DOIUrl":"10.1007/s10549-025-07690-x","url":null,"abstract":"<p><strong>Purpose: </strong>To compare immediate with delayed breast reconstruction in the setting of postmastectomy radiotherapy (PMRT) in terms of the total number of interventions and time required for breast cancer clearance and contour restoration.</p><p><strong>Methods: </strong>The long-term prevalence and number of plannable and urgent interventions required in women receiving PMRT to finish 372 nipple-sparing or skin-sparing mastectomies combined with immediate implant-based breast reconstruction ([N]SSM/IIBR) were compared to those required for 18 mastectomies and delayed breast reconstruction (DBR) performed between 2013 and 2019.</p><p><strong>Results: </strong>Re-interventions were required in 239 of the 372 breasts (64%) after [N]SSM/IIBR, whereas all 18 DBRs (100%) implicitly required at least one re-intervention (p < 0.001). Mastectomy and reconstruction necessitated a mean of 2.24 interventions per breast after [N]SSM/IIBR, which was significantly less than the mean of 3.72 interventions per breast after DBR (p < 0.001). Breast contour reconstruction was achieved in 14.3 months after [N]SSM/IIBR and in 38.6 months after DBR (p < 0.001). [N]SSM/IIBR required more class U3 urgent re-interventions than DBR (22% vs. 4%, p = 0.002), whereas DBR necessitated more class P3 plannable re-interventions (5% vs. 16%, p = 0.004). Initiation of PMRT is not postponed after [N]SSM/IIBR (10.1 weeks) compared to DBR (14.0 weeks).</p><p><strong>Conclusions: </strong>Women potentially needing PMRT should be informed pre-operatively that [N]SSM/IIBR with PMRT may be associated with 22% severe complications and 8% failure. Still, [N]SSM/IIBR prior to PMRT required less interventions and was less time-consuming than DBR following PMRT. Therefore, the potential need of re-interventions should not be the reason for refraining from [N]SSM/IIBR in these women.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"37-46"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}